Phillip Febbo

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Gene expression correlates of clinical prostate cancer behavior
    Dinesh Singh
    Department of Adult Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 1:203-9. 2002
  2. pmc Defining aggressive prostate cancer using a 12-gene model
    Tarek A Bismar
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Neoplasia 8:59-68. 2006
  3. doi request reprint Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression
    Carey K Anders
    Duke University Medical Center, Box 3841, 3829 Duke South, Red Zone, Durham, NC 27710, USA
    J Clin Oncol 26:3324-30. 2008
  4. pmc Literature Lab: a method of automated literature interrogation to infer biology from microarray analysis
    Phillip G Febbo
    Institute for Genome Science and Policy, Duke University, Durham, North Carolina, USA
    BMC Genomics 8:461. 2007
  5. ncbi request reprint Genomic approaches to outcome prediction in prostate cancer
    Phillip G Febbo
    Department of Medicine Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
    Cancer 115:3046-57. 2009
  6. ncbi request reprint Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer
    Phillip G Febbo
    Duke Institute for Genome Sciences and Policy, Division of Medical Oncology Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:152-8. 2006
  7. doi request reprint Genomic strategy for targeting therapy in castration-resistant prostate cancer
    Prateek Mendiratta
    The Duke Institute for Genome Sciences and Policy, Duke Comprehensive Cancer Center, Duke University, Durham, NC 27710, USA
    J Clin Oncol 27:2022-9. 2009
  8. ncbi request reprint Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer
    David S Hsu
    Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC 27710, USA
    J Clin Oncol 25:4350-7. 2007
  9. doi request reprint Cancer gene profiling in prostate cancer
    Adam Foye
    Departments of Medicine and Molecular Genetics and Microbiology, Duke Institute for Genome Science and Policy, Duke University, Durham, NC, USA
    Methods Mol Biol 576:293-326. 2010
  10. doi request reprint Centralized biorepositories for genetic and genomic research
    Geoffrey S Ginsburg
    Center for Genomic Medicine, Duke Institute for Genome Sciences and Policy, Durham, NC 27708, USA
    JAMA 299:1359-61. 2008

Detail Information

Publications40

  1. ncbi request reprint Gene expression correlates of clinical prostate cancer behavior
    Dinesh Singh
    Department of Adult Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 1:203-9. 2002
    ..These results support the notion that the clinical behavior of prostate cancer is linked to underlying gene expression differences that are detectable at the time of diagnosis...
  2. pmc Defining aggressive prostate cancer using a 12-gene model
    Tarek A Bismar
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Neoplasia 8:59-68. 2006
    ..0015). This study demonstrates that cross-platform models can lead to predictive models with the possible advantage of being more robust through this selection process...
  3. doi request reprint Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression
    Carey K Anders
    Duke University Medical Center, Box 3841, 3829 Duke South, Red Zone, Durham, NC 27710, USA
    J Clin Oncol 26:3324-30. 2008
    ..Breast cancer arising in young women is correlated with inferior survival and higher incidence of negative clinicopathologic features. The biology driving this aggressive disease has yet to be defined...
  4. pmc Literature Lab: a method of automated literature interrogation to infer biology from microarray analysis
    Phillip G Febbo
    Institute for Genome Science and Policy, Duke University, Durham, North Carolina, USA
    BMC Genomics 8:461. 2007
    ..e. pathway names, medical subject heading (MeSH) terms, etc)...
  5. ncbi request reprint Genomic approaches to outcome prediction in prostate cancer
    Phillip G Febbo
    Department of Medicine Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
    Cancer 115:3046-57. 2009
    ..Cancer 2009;115(13 suppl):3046-57. (c) 2009 American Cancer Society...
  6. ncbi request reprint Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer
    Phillip G Febbo
    Duke Institute for Genome Sciences and Policy, Division of Medical Oncology Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:152-8. 2006
    ....
  7. doi request reprint Genomic strategy for targeting therapy in castration-resistant prostate cancer
    Prateek Mendiratta
    The Duke Institute for Genome Sciences and Policy, Duke Comprehensive Cancer Center, Duke University, Durham, NC 27710, USA
    J Clin Oncol 27:2022-9. 2009
    ..The variable response to secondary hormonal manipulations in men with castrate-resistant prostate cancer (CRPC) creates a compelling need for strategies to individualize therapy based on the molecular features of each patient's tumor...
  8. ncbi request reprint Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer
    David S Hsu
    Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC 27710, USA
    J Clin Oncol 25:4350-7. 2007
    ..We utilized a genomic strategy to develop signatures predictive of chemotherapeutic response to both cisplatin and pemetrexed to provide a rational approach to effective individualized medicine...
  9. doi request reprint Cancer gene profiling in prostate cancer
    Adam Foye
    Departments of Medicine and Molecular Genetics and Microbiology, Duke Institute for Genome Science and Policy, Duke University, Durham, NC, USA
    Methods Mol Biol 576:293-326. 2010
    ....
  10. doi request reprint Centralized biorepositories for genetic and genomic research
    Geoffrey S Ginsburg
    Center for Genomic Medicine, Duke Institute for Genome Sciences and Policy, Durham, NC 27708, USA
    JAMA 299:1359-61. 2008
  11. doi request reprint Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment
    Christina K Augustine
    Departments of Surgery, Duke University, Durham, NC 27710, USA
    Cancer Res 68:3777-84. 2008
    ..Targeted therapy using an N-cadherin antagonist can dramatically augment the antitumor effects of chemotherapy and is a novel approach to optimizing treatment for melanoma...
  12. ncbi request reprint Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer
    Richard F Riedel
    Duke University Medical Center, Division of Hematology, Department of Medicine, Durham, NC 27710, USA
    Future Oncol 1:461-6. 2005
    ..This finding has extraordinary implications and serves as a critical step toward individualized, patient-specific treatment plans based on the molecular constitution of the tumor of each individual...
  13. ncbi request reprint Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers
    Andrew Berchuck
    Department of Obstetrics and Gynecology Division of Gynecologic Oncology, Institute of Statistics and Decision Sciences, Center for Applied Genomics and Technology, Duke University Medical Center, Durham, North Carolina, USA
    Clin Cancer Res 11:3686-96. 2005
    ..The objective of this study was to define gene expression patterns associated with favorable survival...
  14. doi request reprint Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature
    Andrew J Armstrong
    Department of Medicine and Surgery, Duke Comprehensive Cancer Center, Durham, NC 27710, USA
    Oncologist 14:816-27. 2009
    ....
  15. pmc A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer
    Andrew J Armstrong
    Duke Comprehensive Cancer Center and Duke Prostate Center, Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina 27710, USA
    Clin Cancer Res 16:3057-66. 2010
    ....
  16. pmc Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivo
    Sebastian Oltean
    Department of Molecular Genetics and Microbiology, Duke University Medical Center, Research Drive, Box 3053 424 CARL, Durham, NC 27710, USA
    Clin Exp Metastasis 25:611-9. 2008
    ....
  17. pmc A genomic strategy to elucidate modules of oncogenic pathway signaling networks
    Jeffrey T Chang
    Institute for Genome Sciences and Policy, Duke University Medical Center, Duke University, Durham, NC 27708, USA
    Mol Cell 34:104-14. 2009
    ....
  18. pmc MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy
    Bala S Balakumaran
    Duke Institute for Genome Sciences and Policy and Duke Comprehensive Cancer Center, Duke University, NC 27710, USA
    Cancer Res 69:7803-10. 2009
    ..Taken together, our findings suggest that MYC expression abrogates sensitivity to rapamycin through increased expression of 4EBP1 and reduced autophagy...
  19. doi request reprint Immune signatures predict prognosis in localized cancer
    David S Hsu
    Duke Institute for Genome Sciences and Policy, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Cancer Invest 28:765-73. 2010
    ..05, HR = 0.62). In aggregate, the gene expression signatures implicating specific components of the immune response hold prognostic import across solid tumors...
  20. doi request reprint A genomic approach to identify molecular pathways associated with chemotherapy resistance
    Richard F Riedel
    Duke Institute for Genome Sciences and Policy, Duke University, 2175 CIEMAS Building, Durham, NC 27710, USA
    Mol Cancer Ther 7:3141-9. 2008
    ..These results support the use of a genomic approach to identify drug-specific targets associated with the development of chemotherapy resistance and underscore the importance of disease context in identifying these pathways...
  21. ncbi request reprint MYC activity mitigates response to rapamycin in prostate cancer through 4EBP1-mediated inhibition of autophagy
    Bala S Balakumaran
    Duke University, School of Medicine, Durham, NC, USA
    Autophagy 6:281-2. 2010
    ..It is likely that the genetic context of specific cancers will have an impact upon whether autophagy is primarily a mechanism for survival or cell death...
  22. pmc The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model
    John C Mavropoulos
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Prev Res (Phila) 2:557-65. 2009
    ....
  23. pmc Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma
    Tracy Ann Read
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Cell 15:135-47. 2009
    ..CD15 is also found in a subset of human medulloblastomas, and tumors expressing genes similar to those found in murine CD15(+) cells have a poorer prognosis. Thus, CD15 may represent an important marker for TPCs in medulloblastoma...
  24. ncbi request reprint Genomic signatures associated with the development, progression, and outcome of prostate cancer
    Prateek Mendiratta
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
    Mol Diagn Ther 11:345-54. 2007
    ..This framework has the exciting potential to be predictive and provide personalized and individual treatment to the large number of men diagnosed with prostate cancer each year...
  25. ncbi request reprint New insights into prostate cancer biology
    Bala S Balakumaran
    Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    Hematol Oncol Clin North Am 20:773-96. 2006
    ..Such a characterization is likely to be required to maximize our ability to optimize and individualize preventive and treatment strategies...
  26. pmc Modeling cancer progression via pathway dependencies
    Elena J Edelman
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
    PLoS Comput Biol 4:e28. 2008
    ..A novel finding of our analysis is a connection between ErbB4 and primary prostate cancer...
  27. ncbi request reprint Analysis of sample set enrichment scores: assaying the enrichment of sets of genes for individual samples in genome-wide expression profiles
    Elena Edelman
    Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    Bioinformatics 22:e108-16. 2006
    ..This allows us to assay the natural variation of pathway activity in observed gene expression data sets from clinical cancer and other studies...
  28. ncbi request reprint Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
    Michael Stanbrough
    Cancer Biology Program, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Cancer Res 66:2815-25. 2006
    ..These results indicate that enhanced intracellular conversion of adrenal androgens to testosterone and dihydrotestosterone is a mechanism by which prostate cancer cells adapt to androgen deprivation and suggest new therapeutic targets...
  29. pmc Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model
    Pradip K Majumder
    Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:7841-6. 2003
    ..Thus, the MPAKT model may be useful in studying the role of Akt in prostate epithelial cell transformation and in the discovery of molecular markers relevant to human disease...
  30. ncbi request reprint Use of expression analysis to predict outcome after radical prostatectomy
    Phillip G Febbo
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02118, USA
    J Urol 170:S11-9; discussion S19-20. 2003
    ..We summarize and discuss our recent work exploring the use of gene expression analysis for the prediction of histopathological features of prostate cancer and patient outcome following radical prostatectomy...
  31. ncbi request reprint Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors
    Pamela L Paris
    Comprehensive Cancer Center, University of California at San Francisco, 94115, USA
    Hum Mol Genet 13:1303-13. 2004
    ..Moreover, comparison with an independent set of metastases revealed approximately 40 candidate markers associated with metastatic potential. Copy number aberrations at these loci may define metastatic genotypes...
  32. ncbi request reprint Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer
    Phillip G Febbo
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston Massachusetts 02115, USA
    Clin Cancer Res 11:5233-40. 2005
    ..To determine the clinical, pathologic, and molecular effects of neoadjuvant docetaxel chemotherapy in high-risk localized prostate cancer...
  33. ncbi request reprint Noise and bias in microarray analysis of tumor specimens
    Phillip G Febbo
    J Clin Oncol 24:3719-21. 2006
  34. ncbi request reprint Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors
    James V Alvarez
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 65:5054-62. 2005
    ..Finally, we showed that STAT3 is required for the expression of these genes in a breast cancer cell line. Taken together, these results identify a cohort of STAT3 targets that may mediate its role in oncogenesis...
  35. pmc Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease
    Jing Wang
    Department of Pathology and Medicine, Howard Hughes Medical Institute, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    EMBO J 24:368-81. 2005
    ..This model of MLL-CBP therapy-related myeloproliferative disease demonstrates the selectivity of this MLL fusion for GMP cells and its ability to initiate leukemogenesis in conjunction with cooperating mutations...
  36. ncbi request reprint Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP
    Marshall E Lieberfarb
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 63:4781-5. 2003
    ..This organizational strategy revealed apparently distinct genetic subsets of prostate cancer...
  37. ncbi request reprint Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer
    Phillip G Febbo
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Urol 173:1772-7. 2005
    ..Because AR signaling continues in hormone refractory disease, effector AR target genes may have therapeutic import...
  38. ncbi request reprint mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
    Pradip K Majumder
    Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Med 10:594-601. 2004
    ....
  39. ncbi request reprint Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells
    Raanan Berger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Res 64:8867-75. 2004
    ..These observations indicate that androgen receptor expression is oncogenic and addictive for the human prostate epithelium...
  40. pmc Stromally expressed c-Jun regulates proliferation of prostate epithelial cells
    Wenhua Li
    Department of Urology, Massachusetts General Hospital, Harvard Medical School, Yawkey Bdlg, Suite 7E, 55 Fruit St, Boston, MA 02114 2354, USA
    Am J Pathol 171:1189-98. 2007
    ..Identification of the signal transduction pathways between prostate epithelial cells and the surrounding stromal cells will improve our understanding of the normal and abnormal biology in prostatic diseases...

Research Grants5

  1. Expression Analysis of Prostate Cancer
    Phillip Febbo; Fiscal Year: 2006
    ....
  2. mTOR Therapy in Prostate Cancer: Signatures of Response and Biology of Resistance
    Phillip Febbo; Fiscal Year: 2007
    ..While focused on mTOR response in metastatic prostate cancer, the methods developed and tested in this proposal can be broadly applied. ..
  3. mTOR Therapy in Prostate Cancer: Signatures of Response and Biology of Resistance
    Phillip Febbo; Fiscal Year: 2009
    ..While focused on mTOR response in metastatic prostate cancer, the methods developed and tested in this proposal can be broadly applied. ..
  4. mTOR Therapy in Prostate Cancer: Signatures of Response and Biology of Resistance
    Phillip G Febbo; Fiscal Year: 2010
    ..While focused on mTOR response in metastatic prostate cancer, the methods developed and tested in this proposal can be broadly applied. ..